Disseminated angiomatous lesions in HIV-seropositive patient
More details
Hide details
La Maria Hospital, Medellín, Colombia
Latin American Research Team in Infectiology and Public Health – ELISAP, Medellín, Colombia
Submission date: 2021-12-01
Final revision date: 2022-04-22
Acceptance date: 2022-04-22
Online publication date: 2024-05-18
Corresponding author
Larry Luber Martínez Rosado Luber   

Larry Luber Martínez Rosado, La Maria Hospital, Medellín, Colombia, e-mail:
HIV & AIDS Review 2024;23(2):186-188
Kaposi’s sarcoma is an uncommon malignant vascular neoplasm linked to human herpesvirus type 8 (HHV-8); it is a tumor characterized by proliferation of HHV-8-associated spindle cells and abnormal neo-vasculature. Although Kaposi’s sarcoma has been described in immunocompetent subjects, strong inter-relationships with host immunity lead to higher prevalence in people living with human immunodeficiency virus (HIV). HIV infection has been historically associated with malignancies, such as Kaposi’s sarcoma. Usually, it causes abnormalities that develop in tissues below the skin surface anywhere on the body or in mucous membranes of the mouth. Some authors have observed that malignancy is becoming a major cause of death among HIV-infected individuals in industrialized nations. In non-industrialized countries, profound weaknesses have been demonstrated in the diagnostic muscle of infectious diseases in general, with viral diseases being no exception. Treatment may consist of surgery, chemotherapy, or a combination of these treatment techniques. Combination of two or more of these treatment methods has become an important approach for increasing patient’s chance of cure and prolonging survival. There are four clinical presentations: classic, endemic, associated with iatrogenic immunosuppression, and associated with acquired immunodeficiency syndrome. This article presented a clinical case of an HIV-seropositive patient affected by disseminated angiomatous lesions, diagnosis, therapeutic options, and evolution.
Tappero JW, Koehler JE. Bacillary angiomatosis or Kaposi’s sarcoma? N Engl J Med 1997; 337: 1888-1888.
Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 2011; 71: 3831-3840.
Koelle DM, Pauk J, Selke S, Wald A, Corey L, Huang ML, et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 2002; 343: 1369-1377.
Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002; 94: 1204-1210.
Kowalkowski MA, Kramer JR, Richardson PR, Suteria I, Chiao EY. Use of boosted protease inhibitors reduces kaposi sarcoma incidence among male veterans with HIV infection. Clin Infect Dis 2015; 60: 1405-1414.
Régnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol 2013; 68: 313-331.
Journals System - logo
Scroll to top